Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-19 (University of Sao Paulo)
- Development stage
- Unknown
- Lead developer
- Universidade de São Paulo
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CART-19 (University of Sao Paulo) is an academic, autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The therapy involves the genetic modification of a patient's own T lymphocytes using a lentiviral vector to express a second-generation CAR. This receptor consists of a single-chain variable fragment (scFv) specific for the CD19 antigen, linked to 4-1BB (CD137) co-stimulatory and CD3-zeta signaling domains. Once infused back into the patient, these modified T cells recognize and eliminate CD19-expressing B-cells. The product is manufactured locally in Brazil at facilities such as Nutera-São Paulo and Nutera-Ribeirão Preto to increase accessibility within the Brazilian Unified Health System (SUS).
- Other names
- academic CART-19CD19-directed CAR-T cell therapyCD-19-directed CAR-T cell therapyCD 19-directed CAR-T cell therapy
02
Targets
Beyond the preview
Go deeper on CART-19 (University of Sao Paulo).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-19 (University of Sao Paulo).